Erlotinib

Details

Files

Generic Name:

Erlotinib

Project Status:

Complete

Therapeutic Area:

Cancer, Lung , non-small cell

Manufacturer:

Hoffmann-La Roche Limited

Brand Name:

Tarceva

Project Line:

Reimbursement Review

Project Number:

SR0037-000

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Initial

Indications:

Cancer, Lung , non-small cell

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

December 7, 2005

Recommendation:

List for patients with NSCLC after failure of at least one prior chemotherapy regimen, and whose EGFR expression status is positive or unknown.

Last Updated : July 19, 2005